Auriga Partners
VC Fund
Paris, France
Auriga Partners is a VC fund in Paris focused on Biotechnology and Health Care. Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.
- Total investments:
- 128
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Auriga Partners invests in
BiotechnologyHealth CareMedicalSoftwarePharmaceutical
Stages Auriga Partners invests in
Series BSeries AFunding RoundSeries CSeries D
Countries Auriga Partners invests in
FranceUnited StatesSwitzerlandSwedenUnited Kingdom
Round sizes
Series A $2.2M–$14MSeries B $3.8M–$33M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.2M–$14M
- Series B
- $3.8M–$33M
Investment Focus
Industry
- Biotechnology 33 (26%)
- Health Care 19 (15%)
- Medical 14 (11%)
- Software 13 (10%)
- Pharmaceutical 12 (9%)
Stage
- Series B 33 (26%)
- Series A 24 (19%)
- Funding Round 21 (16%)
- Series C 17 (13%)
- Series D 7 (5%)
Country
- France 47 (37%)
- United States 10 (8%)
- Switzerland 3 (2%)
- Sweden 2 (2%)
- United Kingdom 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Sébastien Descarpentries
Partner
|
Partner | Total investments: 1 | Find email | |
Anne Sossou Hounto
Legal assistant
|
Legal assistant | Total investments: 0 | Find email | |
Arnaud-Guilhem Le Ribault
Partner
|
Partner | Total investments: 0 | Find email | |
Bernard Daugeras
Co-founder
|
Co-founder | Total investments: 5 | Find email | |
Françoise Lugand
Office manager
|
Office manager | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Exeliom
|
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $8.7M / Series A / Jun 30, 2023 | |
Patrowl
|
Patrowl is an innovative product designed by cybersecurity experts. It automates the detection and remediation of your vulnerabilities to finally be faster and more efficient than cybercriminal organizations.It is built around 4 main principles: - Thanks to Artificial Intelligence coupled with our expertise, Patrowl automates continuouspenetration tests. This allows us to identify your assets (known and shadow-it) and vulnerabilities in real time over a wide area. - At a glance, visualize your overall level of security and especially how to improve it. - Real adapted solutions appear on the Dashboard. You will be able to act yourself or quickly transmit the solution directly to the teams concerned and follow the remediation. - Then Patrowl lets you make sure everything has been fixed with one click, by retesting.This solution is simple, easy to learn and makes cybersecurity accessible to everyone. Our watchword: demotivate cybercriminals | $2.1M / Seed / Jun 24, 2022 | |
Vade Secure
|
Vade Secure is the global leader on anti-phishing, spear phishing, malware and ransomware with heuristic filtering. Language independent, the filter analyzes globally all incoming emails (links, attached files, content…) to detect all threats in zero-day, even the most targeted attacks. After elimination all threats, we eliminate the nuisance oflow priority emails with the Graymail Management. Ads, social networks notifications, and newsletters are automatically sent to the graymail folder while the Safe Unsubscribe button eliminate them forever.Protecting more than 500 million of mailboxes in 76 countries, our solutions are used by major ISPs, OEMs, and Enterprises worldwide. Vade Secure is implanted in 5 countries (USA, Canada, France, Hong Kong, and Japan) to offer a 24/7 support.For more information, please visit www.vadesecure.com/en. | $30.1M / Venture - Series Unknown / May 31, 2022 | |
|
Exeliom
|
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $7.7M / Series A / Jul 06, 2018 | |
Flash Therapeutics
|
Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform. | $3.6M / Private Equity / May 16, 2018 | |
EnobraQ
|
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics. | $3.2M / Seed / Apr 10, 2018 | |
Pherecydes Pharma
|
Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $9.5M / Series B / Jan 16, 2018 | |
aveni
|
aveni delivers innovative metallization processes that improve device performance and yield, enabling future technologies, today. Their production-ready solutions revolutionize the copper-plating process for damascene and TSV applications critical to semiconductor and MEMS device manufacturing. aveni’s Electrografting (eG™) technology is a wet,electrochemical-based process that enables the growth of extremely high-quality thin films of various types. Chemicalgrafting (cG™) is based on the same fundamental mechanisms as Electrografting, but is used on nonconductive substrates. Both technologies have been successfully demonstrated in manufacturing at and below the 14 nm node, as well as 40:1 aspect ratios.The company was originally founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA) to develop and market groundbreaking nanometric deposition technologies for a variety of electronic applications. Since that time, aveni has partnered with several R&D centers, and leading global equipment and device manufacturers on a variety of projects. Based in Massy, France, the company has a strong team of scientists and engineers who excel in the fields of surface science, chemistry, electrochemistry, physics, materials science and semiconductors. | $9.4M / Series B / Oct 24, 2017 | |
Vectalys
|
Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwideunderstand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues.Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest.Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects. | $1.6M / Jun 13, 2017 | |
VitaDX
|
VitaDX is a startup applying artificial intelligence to the healthcare sector, and more specifically to the early diagnosis of cancer by exploiting fluorescence imaging in favor of a first product, VisioCyt®, dedicated to the detection of cancer of the bladder. This solution will allow the diagnosis of bladder cancer from a simple urine sample toimprove the performance of urinary cytology conventionally used in first intention. | $1.8M / Seed / Jun 06, 2017 | |
| See all 128 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does Auriga Partners invest in?
Auriga Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 128 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Auriga Partners's check size?
Auriga Partners typically joins rounds of $2.2M–$14M at Series A and $3.8M–$33M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Auriga Partners participates in.
How do I contact Auriga Partners?
Public channels for Auriga Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Auriga Partners?
The team at Auriga Partners includes Sébastien Descarpentries (Partner), Anne Sossou Hounto (Legal assistant) and Arnaud-Guilhem Le Ribault (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
